Pancreatic β-cell imaging in humans: fiction or option?
| Autor: | G. Filhoulaud, Sabine Sewing, H. Glombik, H.-P. Juretschke, Haiyan Wang, Guy A. Rutter, M. Daval, P. Hecht, Didier Laurent, Paolo Meda, Laurent Vinet, Smaragda Lamprianou, Xavier Montet, A. Ktorza, W. Kramer, J. Hecksher-Sørensen, Nicholas J. Long, R. Boisgard, Graeme J. Stasiuk, D. L. Nguyen |
|---|---|
| Přispěvatelé: | The Royal Society, Wellcome Trust, Medical Research Council (MRC) |
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
type 1 diabetes PSA-NCAM Endocrinology Diabetes and Metabolism Disease Type 2 diabetes Sulfonylurea Receptors PEPTIDE-1 RECEPTOR Mice Endocrinology Insulin-Secreting Cells Health care ADHESION MOLECULE IN-VIVO GLP-1 analogue islets Membrane Glycoproteins EXOCRINE PANCREAS ENDOCRINE PANCREAS Molecular Imaging Zinc Drug development sulphonylureas Life Sciences & Biomedicine Adult medicine.medical_specialty Glucagon-Like Peptide-1 Receptor 03 medical and health sciences Endocrinology & Metabolism VMAT2 POSITRON-EMISSION-TOMOGRAPHY Internal medicine Diabetes mellitus Internal Medicine medicine Cell Adhesion Diabetes Mellitus Animals Humans TRANSGENIC MOUSE MODEL Intensive care medicine Goal achieved Type 1 diabetes Manganese Science & Technology business.industry Disease mechanisms DIABETES-MELLITUS 1103 Clinical Sciences medicine.disease beta cell Rats 030104 developmental biology Vesicular Monoamine Transport Proteins Luminescent Measurements RAT PANCREAS business |
| Zdroj: | Diabetes, obesitymetabolism. 18(1) |
| ISSN: | 1463-1326 |
| Popis: | Diabetes mellitus is a growing worldwide epidemic disease, currently affecting 1 in 12 adults. Treatment of disease complications typically consumes ∼10% of healthcare budgets in developed societies. Whilst immune-mediated destruction of insulin-secreting pancreatic β cells is responsible for Type 1 diabetes, both the loss and dysfunction of these cells underly the more prevalent Type 2 diabetes. The establishment of robust drug development programmes aimed at β-cell restoration is still hampered by the absence of means to measure β-cell mass prospectively in vivo, an approach which would provide new opportunities for understanding disease mechanisms and ultimately assigning personalized treatments. In the present review, we describe the progress towards this goal achieved by the Innovative Medicines Initiative in Diabetes, a collaborative public-private consortium supported by the European Commission and by dedicated resources of pharmaceutical companies. We compare several of the available imaging methods and molecular targets and provide suggestions as to the likeliest to lead to tractable approaches. Furthermore, we discuss the simultaneous development of animal models that can be used to measure subtle changes in β-cell mass, a prerequisite for validating the clinical potential of the different imaging tracers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text